Stockscreener 앱 받기
39.23
0.22%
0.12
전일 마감가:
$39.11
열려 있는:
$39.43
하루 거래량:
38,383
Relative Volume:
0.04
시가총액:
$1.80B
수익:
-
순이익/손실:
$-146.66M
주가수익비율:
-14.24
EPS:
-2.7541
순현금흐름:
$-133.21M
1주 성능:
+5.53%
1개월 성능:
-6.59%
6개월 성능:
+0.71%
1년 성능:
-21.91%
1일 변동 폭
$39.07
$39.91
1주일 범위
$37.40
$40.40
52주 변동 폭
$26.20
$63.50
Apogee Therapeutics Inc Stock (APGE) Company Profile
명칭
Apogee Therapeutics Inc
전화
650-394-5230
주소
221 CRESCENT ST., WALTHAM
APGE을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
APGE
Apogee Therapeutics Inc
|
39.20 | 2.27B | 0 | -146.66M | -133.21M | -2.7541 |
|
VRTX
Vertex Pharmaceuticals Inc
|
466.39 | 121.30B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
557.52 | 61.60B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
322.26 | 41.17B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
569.31 | 34.35B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
292.00 | 27.29B | 3.81B | -644.79M | -669.77M | -6.24 |
Apogee Therapeutics Inc Stock (APGE) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-07-07 | 재확인 | BTIG Research | Buy |
| 2025-03-13 | 개시 | Citigroup | Buy |
| 2024-11-25 | 개시 | Canaccord Genuity | Buy |
| 2024-05-10 | 개시 | BofA Securities | Buy |
| 2023-12-20 | 개시 | BTIG Research | Buy |
| 2023-08-08 | 개시 | Guggenheim | Buy |
| 2023-08-08 | 개시 | Jefferies | Buy |
| 2023-08-08 | 개시 | Stifel | Buy |
| 2023-08-08 | 개시 | TD Cowen | Outperform |
| 2023-08-08 | 개시 | Wedbush | Outperform |
모두보기
Apogee Therapeutics Inc 주식(APGE)의 최신 뉴스
What analysts say about Apogee Therapeutics Inc. stockFree Investment Portfolio Suggestions - jammulinksnews.com
InvestingPro Fair Value model captures 43% downside in Apogee Therapeutics By Investing.com - Investing.com Canada
Is Apogee Therapeutics Inc. a good long term investmentOutstanding capital returns - jammulinksnews.com
Apogee Therapeutics Inc. Stock Analysis and ForecastFree Investment Community - jammulinksnews.com
What drives Apogee Therapeutics Inc. stock priceFree Stock Market Knowledge Sharing - Autocar Professional
Teacher Retirement System of Texas Sells 629 Shares of Apogee Therapeutics Inc. (NASDAQ:APGE) - Defense World
BTIG Raises PT on Apogee Therapeutics (APGE) to $115 From $100, Keeps a Buy Rating - MSN
Will Apogee Therapeutics Inc. stock benefit from interest rate changesTop Gaining Low Risk Assets - Newser
12 Oversold NASDAQ Stocks to Buy Now - Insider Monkey
Apogee Therapeutics (APGE) Falls 17%, Positive Trial Results Fail to Impress Investors - MSN
What makes Apogee Therapeutics Inc. stock price move sharplyFree Stock Selection - Newser
Why Apogee Therapeutics Inc. stock attracts strong analyst attentionLow Risk Stock Strategies - Newser
How Apogee Therapeutics Inc. stock performs during market volatilityStable Growth Stock Picks - Newser
Canaccord Genuity Reiterated a Buy Rating on Apogee Therapeutics (APGE) - Insider Monkey
Analysts Set Apogee Therapeutics Inc. (NASDAQ:APGE) Price Target at $99.00 - Defense World
Rx Rundown: Merck, Gilead Sciences, Apogee Therapeutics and more - Medical Marketing and Media
Stifel reiterates Buy rating on Apogee Therapeutics stock amid positive AD data - Investing.com Nigeria
Trend Tracker for (APGE) - news.stocktradersdaily.com
Apogee Therapeutics (NASDAQ:APGE) Earns "Outperform" Rating from Wedbush - MarketBeat
Apogee falls after results from atopic dermatitis trial - MSN
Canaccord Genuity reaffirms Buy rating on Apogee Therapeutics stock after positive trial data - Investing.com Canada
Apogee Therapeutics: Funding Supports Best-In-Class Ambitions In Atopic Dermatitis (APGE) - Seeking Alpha
Gold Falls 1%; ProKidney Shares Spike HigherApogee Therapeutics (NASDAQ:APGE), Blue Gold (NASDAQ:BGL) - Benzinga
Canaccord Genuity reaffirms Buy rating on Apogee Therapeutics stock after positive trial data By Investing.com - Investing.com South Africa
Jefferies raises Apogee Therapeutics stock price target to $96 on promising trial data - Investing.com Nigeria
Jefferies raises Apogee Therapeutics stock price target to $96 on promising trial data By Investing.com - Investing.com South Africa
Apogee Therapeutics shares fall 1.66% in premarket after profit-taking and technical selling. - AInvest
Positive Phase II APEX clinical trial of Apogee’s APG777 - The Pharma Letter
Apogee Therapeutics’ (APGE) Outperform Rating Reaffirmed at Wedbush - Defense World
Apogee Therapeutics Target of Unusually Large Options Trading (NASDAQ:APGE) - Defense World
Apogee Therapeutics stock maintains Buy rating at Citi after positive data - Investing.com India
Apogee Therapeutics stock maintains Buy rating at Citi after positive data By Investing.com - Investing.com South Africa
Dow Dips 1%; Mustang Bio Shares Spike Higher - Benzinga
APGE Makes Notable Cross Below Critical Moving Average - Nasdaq
Apogee Therapeutics Shares Positive Interim Phase 1b Results for APG808 in Asthma - MSN
Apogee Therapeutics reports positive Phase 2 results for atopic dermatitis drug - Proactive financial news
Apogee Therapeutics Inc (APGE) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Apogee Therapeutics Inc 주식 (APGE) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Dambkowski Carl | Chief Medical Officer |
Jul 02 '25 |
Sale |
45.09 |
10,090 |
454,954 |
238,998 |
0.14%
0.65%
자본화:
|
볼륨(24시간):